Arca
Skip to content

Malignancies

Drug research and approvals for malignancies: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 18,858 studies of malignancies are recruiting on ClinicalTrials.gov, Health Canada has authorized 91 drug trials for it since 2013, FDA has 5 approved and 11 open orphan designations naming it, and the EU has 23 authorised medicines for it.

  • Recruiting worldwide: 18,858
  • Trials authorized in Canada: 91
  • FDA orphan approvals: 5
  • EU medicines: 23

Recruiting Now

Newest start dates first, of 18,858 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 91; search them all in Canada trials
Nov 13, 2026Dualis: a modular phase I/ii, open-label, multicentre study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and…AZD1221AstraZeneca Pharmaceuticals LPPending
Sep 4, 2026Baf_frontier-1, a first-in-human, phase 1 trial to assess safety, tolerability, and preliminary efficacy of ly4152199, a b-cell activation factor receptor…LY4152199Eli LillyPending
Jul 15, 2026A phase 3, prospective, open-label, multicenter, single-arm study to investigate the efficacy, safety, and pharmacokinetics of igpro20 in subjects with…HIZENTRACSLPending
Apr 23, 2026An open-label phase 1 study to evaluate pf-07994525 in participants with advanced malignanciesPF-07994525PfizerOngoing
Oct 24, 2025A phase 1b / 2, multicenter, multi arm study of evorpacept in combination with anti-cancer therapies in advanced / metastatic malignancies / a single-arm phase…EVORPACEPT (ALX148) /TRASTUZUMAB / TARO-CAPECITABINE / HALAVEN (ERIBULIN) /…ALX ONCOLOGY INC.Ongoing
Oct 8, 2025An open-label phase 1 study to evaluate pf-08046037 as monotherapy and part of combination therapy in participants with advanced malignanciesPF-08046037 / SASANLIMAB (PF-06801591)PfizerClosed
Sep 11, 2025Help-study - towards high throughput and efficient long-axial pet with oral [18f]fdgFLUDEOXYGLUCOSE (18F)BC CANCER, PART OF THE PROVINCIAL HEALTH SERVICES AUTHORITY - VANCOUVER CENTEROngoing
Sep 10, 2025Study of azd3632 monotherapy or in combination with anticancer agents in participants with advanced haematologic malignancies with kmt2ar, npm1m, or other…AZD3632AstraZeneca Pharmaceuticals LPPending
Oct 25, 2024A phase 1/1b first-in-human trial of bms-986484 as monotherapy and combination therapy in participants with advanced solid malignanciesBMS-986484 / OPDIVOBristol-Myers SquibbOngoing
Aug 15, 2024Lightbeam-u01 substudy 01a: a phase 1/2 substudy to evaluate the safety and efficacy of zilovertamab vedotin in pediatric and young adult participants with…ZILOVERTAMAB VEDOTIN (MK-2140) / PATRITUMAB DERUXTECAN / IFINATAMAB DERUXTECANMerck & Co. (MSD)Ongoing

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 16
Apr 17, 2023Omisirgefor use in adults and pediatric patients 12 years and older with hematologic malignancies who are planned for umbilical cord blood…Gamida Cell Ltd.Approved
Jul 12, 2002ElitekInitial management of plasma uric acid levels in pediatric patients with leukemia,lymphoma, and solid tumor malignancies who are receiving…Sanofi-Synthelabo ResearchApproved
Feb 4, 1999BusulfexFor use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation…Otsuka Pharmaceutical Company, LtdApproved
May 17, 1996Aloprim for InjectionManagement of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of…Catalytica Pharmaceuticals, IncApproved
Jun 15, 1994NeupogenReduce the duration of neutropenia and neutropenia sequelae in patients with non-myeloid malignancies undergoing ablative chemotherapy…Amgen, Inc.Approved
Nov 14, 2023mocravimodTreatment to improve outcome following hematopoietic stem cell transplantation in hematologic malignanciesPriothera SASDesignated
Jun 24, 2013liposomal busulfanFor use as a conditioning regimen for patients with malignancies undergoing autologous or allogeneic hematopoietic stem cell transplantationCalliditas Therapeutics ABDesignated
Apr 6, 2012ferumoxytolFor use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric…ArsNova Partners, LLCDesignated
Sep 12, 2008Human Allogeneic HLA-matched, Umbilical Cord Blood…Treatment of insufficient hematopoietic stem cell production in patients with hematologic malignancies who have failed treatment with…Mesoblast, Inc.Designated
Apr 27, 2007Attenuated autologous cancer cells and granulocyte…Treatment of primary central nervous system malignanciesTVAX Biomedical, LLCDesignated
Jul 3, 2000CarmustineTreatment of intracranial malignancies.Direct Therapeutics, Inc.Designated
Feb 27, 1998ThalidomideTreatment of primary brain malignancies.Celgene CorporationDesignated
Jul 7, 1997BusulfanTreatment of primary brain malignancies.SuperGen, Inc.Designated
Apr 21, 1994BusulfanFor use as preparative therapy for malignancies treated with bone marrow transplantation.Sparta Pharmaceuticals, Inc.Designated
Sep 7, 1988Serratia marcescens extract (polyribosomes)Treatment of primary brain malignancies.Cell Technology, Inc.Designated

Medicines Authorised in the EU

Newest first; 15 of 23
Aug 28, 2026Denosumab Ascenddenosumab · biosimilarAscend GmbHEMA ↗
Nov 17, 2025Degevmadenosumab · biosimilarTeva GmbHEMA ↗
Nov 17, 2025Xbonzydenosumab · biosimilarReddy Holding GmbHEMA ↗
Nov 17, 2025Zvogradenosumab · biosimilarStada Arzneimittel AGEMA ↗
Sep 17, 2025Bilprevdadenosumab · biosimilarSciencepharma Sp. z o.oEMA ↗
Aug 25, 2025Zemcelproallogeneic umbilical cord-derived CD34- cells, non-expanded;dorocubicel · orphanCordex Biologics International LimitedEMA ↗
Jul 17, 2025Bomyntradenosumab · biosimilarFresenius Kabi Deutschland GmbHEMA ↗
Jun 26, 2025Denbraycedenosumab · biosimilarMabxience Research SLEMA ↗
Jun 26, 2025Enwylmadenosumab · biosimilarZentiva k.s.EMA ↗
Jun 25, 2025Vevzuodenosumab · biosimilarBiosimilar Collaborations Ireland LimitedEMA ↗
Jun 23, 2025Yaxwerdenosumab · biosimilarGedeon Richter Plc.EMA ↗
May 26, 2025Jubereqdenosumab · biosimilarAccord Healthcare S.L.U.EMA ↗
Feb 14, 2025Osenveltdenosumab · biosimilarCelltrion Healthcare Hungary Kft.EMA ↗
Feb 12, 2025Xbrykdenosumab · biosimilarSamsung Bioepis NL B.V.EMA ↗
May 17, 2024Wyostdenosumab · biosimilarSandoz GmbHEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.